Last updated: February 16, 2026
Product Overview
NDC 59651-0566 corresponds to Tazemetostat, a targeted EZH2 inhibitor approved by the FDA for specific cancers. It is marketed under the brand name Tazverik by Epizyme. The drug addresses epithelioid sarcoma and follicular lymphoma, with recent extensions into additional indications. It received accelerated approval in January 2020.
Market Landscape
-
Indications and Approved Population
The dominant indications are epithelioid sarcoma and follicular lymphoma. The primary target populations include approximately 100,000 patients globally, with larger unmet needs in rare and resistant tumor subsets.
-
Competitive Environment
Tazemetostat faces competition from other EZH2 inhibitors (e.g., GSK’s GSK126, Novartis’s CPI-1205) and broader epigenetic drugs like HDAC inhibitors. Its unique approval for rare cancers offers a product niche, with potential expansion driven by ongoing trials.
-
Prescribing Trends
Market penetration remains low, with approximately 15-20% of eligible patients receiving the drug, constrained by factors including diagnosis delay, pricing, and treatment access.
-
Regulatory Developments
Recent FDA approvals for additional indications and ongoing phase 3 trials targeting solid tumors and other hematologic malignancies could expand the market in the coming years.
Pricing Analysis
-
Current Pricing
The wholesale acquisition cost (WAC) for Tazverik is approximately $16,598 per 28-day cycle (based on public sources as of early 2023) [1]. Price consistency has been maintained since launch, with no significant discounts publicly reported.
-
Cost per Patient
Estimated annual treatment cost per patient approximates $200,000, assuming continuous therapy and stable dosing.
-
Reimbursement Environment
Insurance coverage and patent protections influence net prices. Limited competition in rare cancers supports premium pricing, but constraints exist due to negotiations and value assessments.
Market Projections (2023-2028)
| Year |
Estimated Patients |
Revenue (USD millions) |
Assumptions |
| 2023 |
1,200 |
288 |
Launch year, initial uptake limited to target populations |
| 2024 |
2,000 |
480 |
Expanded approvals and increased prescriber adoption |
| 2025 |
3,000 |
720 |
Continued growth, broader indications, increased awareness |
| 2026 |
4,200 |
1,008 |
Full market penetration in initial indications |
| 2027 |
5,000 |
1,200 |
Potential new indications and expanded payer approval |
| 2028 |
6,000 |
1,440 |
Further indication approvals and increased clinical use |
Factors Impacting Price and Volume
- Regulatory Approvals: New indications could increase accessible patient populations.
- Clinical Trial Outcomes: Positive results could lead to label expansion, driving demand.
- Market Access & Reimbursement: Price negotiations could contain growth if reimbursement rates tighten.
- Competitive Dynamics: Introduction of competing therapies could compress prices and limit growth.
Key Drivers and Risks
- Positive trial results and regulatory approvals could substantially increase market size and revenues.
- Pricing pressures from payers or emerging generics could lower unit price.
- Limited patient pool constrains overall revenue growth despite increasing prices.
Summary
NDC 59651-0566, Tazemetostat, holds a niche in rare cancer treatment with a pricing baseline around $16,598 per month. Market projections suggest steady growth driven by indication expansion and clinical trial success, with potential annual revenues reaching $1.4 billion by 2028 assuming current pricing strategies persist and the addressable patient population expands as expected.
Key Takeaways
- Tazemetostat is a targeted therapy for rare tumors, with limited direct competition.
- Current pricing remains stable around $16,598 per cycle.
- Market size is expected to grow from approximately 1,200 patients in 2023 to 6,000 by 2028.
- Revenue projections indicate potential annual sales exceeding $1.4 billion in five years.
- Market expansion depends on new indications, clinical results, and reimbursement strategies.
FAQs
-
What factors could cause Tazemetostat's price to decrease?
Increased competition, inclusion of biosimilars or generics, and payer pressure to reduce costs could lead to price reductions.
-
How does Tazemetostat compare to other epigenetic drugs?
It is one of the few approved EZH2 inhibitors targeting specific tumor types, offering a distinct niche compared to broader epigenetic modifiers.
-
Are there plans for new indications?
Ongoing clinical trials aim to expand its use in solid tumors, lymphoma subtypes, and other cancers, potentially broadening market size.
-
What are the main barriers to market growth?
The small patient population, limited awareness, and reimbursement hurdles limit rapid growth.
-
When could generic competition emerge?
Patent exclusivity lasts until 2037, with no current generic entrants anticipated before then.
References
[1] Public pricing data, IQVIA, 2023.
